Also found in: Dictionary.
Related to Efexor: Wellbutrin

venlafaxine hydrochloride

Co Venlafaxine, Co Venlafaxine XR, Efexor (UK), Effexor, Effexor XR, Gen-Venlafaxine XR, Novo-Venlafaxine XR, PMS-Venlafaxine XR, Ratio-Venlafaxine XR, Riva-Venlafaxine XR, Sandoz Venlafaxine XR

Pharmacologic class: Phenethylamine derivative

Therapeutic class: Antidepressant, anxiolytic

Pregnancy risk category C


Inhibits neuronal serotonin and norepinephrine reuptake and slightly inhibits dopamine reuptake


Capsules (extended-release): 37.5 mg, 75 mg, 150 mg

Tablets: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg

Tablets (extended-release): 37.5 mg, 75 mg, 150 mg, 225 mg

Indications and dosages


Adults: In outpatients, 75 mg P.O. daily in two or three divided doses; may increase in increments of 75 mg/day q 4 or more days to a maximum of 225 mg/day; extended-release form can be given as a single daily dose. In hospitalized patients, 75 mg P.O. daily in two or three divided doses; may increase in increments of 75 mg/day q 4 days to a maximum of 375 mg/day given in three divided doses.

Generalized anxiety disorder

Adults: Single dose of 37.5 to 75 mg (extended-release) P.O. daily; may increase in increments of 75 mg/day q 4 days to a maximum of 225 mg/day

Panic disorder

Adults: 37.5 mg (extended-release) P.O. daily for 7 days; increase to 75 mg P.O. daily for 7 days; then increase by 75 mg daily at weekly intervals to a maximum of 225 mg P.O. daily

Social anxiety disorder

Adults: 75 mg (extended-release capsule) P.O. daily as a single dose

Dosage adjustment

• Hepatic or renal impairment

Off-label uses

• Premenstrual dysphoric disorder


• Hypersensitivity to drug

• MAO inhibitor use within past 14 days


Use cautiously in:

• cardiovascular disease; hypertension; heart failure, recent myocardial infarction, and other conditions in which increased heart rate poses a danger; hepatic or renal impairment; glaucoma; hyperthyroidism; hyponatremia; syndrome of inappropriate antidiuretic hormone secretion (SIADH)

• history of seizures, neurologic impairment, or drug abuse

• pregnant or breastfeeding patients

• children younger than age 18.


Don't give within 14 days of MAO inhibitors.

Adverse reactions

CNS: abnormal dreams, anxiety, dizziness, headache, insomnia, nervousness, abnormal thinking, agitation, confusion, depersonalization, drowsiness, emotional lability, worsening depression, twitching, tremor, asthenia, paresthesia, mania, hypomania, suicidal ideation or behavior (especially in child or adolescent)

CV: chest pain, hypertension, palpitations, tachycardia, vasodilation

EENT: visual disturbances, blurred vision, mydriasis, tinnitus, rhinitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia

GU: urinary frequency or retention, sexual dysfunction, abnormal ejaculation, anorgasmia, erectile dysfunction

Metabolic: hyponatremia, SIADH

Skin: bruising, pruritus, rash, diaphoresis, photosensitivity

Other: altered taste, weight loss, chills, yawning


Drug-drug. Cimetidine: increased venlafaxine effects

MAO inhibitors: potentially fatal reactions

Sumatriptan, trazodone: serotonin syndrome (including altered level of consciousness)

Drug-diagnostic tests. Sodium: decreased level

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

S-adenosylmethionine (SAM-e), St. John's wort: increased risk of sedative or hypnotic effects

Patient monitoring

Monitor neurologic status, particularly for seizures, worsening depression, and suicidal ideation.

• Closely monitor vital signs and cardiovascular status. Stay alert for hypertension and tachycardia.

• Monitor nutritional status, hydration, and weight.

Patient teaching

• Tell patient taking extended-release capsules to swallow them whole without chewing, breaking, dividing, or dissolving.

Caution patient not to stop therapy abruptly.

Advise patient to promptly report seizures, worsening depression, or suicidal thoughts (especially in child or adolescent).

• Caution patient to avoid driving and other dangerous activities until drug effects are known.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A brand name for VENLAFAXINE.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Now The Committee on Safety of Medicines, responsible for regulating drugs, has issued a warning to GPs about similar risks from the drug Efexor.
Pharmaceutical manufacturers push feel-good drugs with positively futuristic names: Prozac, Aropax, Efexor, Luvox and Serzone.
The company introduced three new products namely Tazocin, Efexor and Monotrate during the last quarter of the year under review.
There are four types of anti-depressants: Tricyclics, such as Tryptizol (the cheapest, as you'll see from our guide on the right) and Anafranil; Mono amine oxidase inhibitors (MAOIs), such as Nardil and Parnate; Selective Serotonin Reuptake Inhibitors (SSRIs) such as Prozac and Lustral (the most expensive); and Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs), such as Efexor.
Specific interventions involve: both two groups were given orally Venlafaxine Hydrochloride Sustainedrelease Tablets (EFEXOR XR, Pfizer) 75mg per day, and lorazepam 1.0 mg orally twice per day, in the morning and night.
Perhaps more worrying, some of the drugs involved - Prozac, Seroxat and Efexor - have also been allegedly linked to a host of side-effects, including suicide.
Colleagues at the Efexor factory in Newbridge praised Mark's honesty.
Mental health campaigners yesterday voiced 'deep concern' over a widely-used class of antidepressant drugs after medical authorities said the treatment Efexor should not be given to under-18s.
The Medicines and Healthcare products Regulatory Agency said anti-depressant Efexor should not be prescribed for children after research showed it provoked hostile behaviour and had no significant benefits.
They included antide-pressants regularly prescribed in the UK, including fluoxetine (Prozac), venla-faxine (Efexor) and paroxet-ine (Seroxat).
Seroxat (paroxetine), Prozac (fluoxetine),Lustral (sertraline), Edronax (reboxetine), Efexor (Venlafaxine)
In September the SSRI Efexor (venflaxine) was banned for use in under-18s.